Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Neoplasm, Residual × Zoledronic Acid × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Prostatic Neoplasms 11 Breast Neoplasms 9 Neoplasm Metastasis 6 Multiple Myeloma 5 Osteoporosis 4 Carcinoma, Renal Cell 3 Carcinoma, Non-Small-Cell Lung 3 Ovarian Neoplasms 2 Lung Neoplasms 2 Kidney Neoplasms 2 Uterine Cervical Neoplasms 1 Urologic Neoplasms 1 Small Cell Lung Carcinoma 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Pleural Effusion, Malignant 1 Osteonecrosis 1 Oligodendroglioma 1 Neovascularization, Pathologic 1 Neoplasms, Plasma Cell 1 Neoplasms by Site 1 Neoplasms 1 Neoplasm, Residual 1 Neoplasm Micrometastasis 1 Nasopharyngeal Neoplasms 1 Myelodysplastic Syndromes 1 Mesothelioma 1 Lymphoma 1 Leukemia 1 Hereditary Breast and Ovarian Cancer Syndrome 1 Gliosarcoma 1

Interventions

blinatumomab 7 Cyclophosphamide 6 Rituximab 5 Lenalidomide 5 Dexamethasone 5 fludarabine 4 Azacitidine 4 venetoclax 3 fludarabine phosphate 3 Cytarabine 3 thymoglobulin 2 obinutuzumab 2 daratumumab 2 Whole-Body Irradiation 2 N,N-dicyclohexyl-isoborneol-10-sulfonamide 2 Methotrexate 2 Melphalan 2 Immunotherapy 2 Imatinib Mesylate 2 Clofarabine 2 Cladribine 2 Calcium Dobesilate 2 Busulfan 2 treosulfan 1 trastuzumab deruxtecan 1 tislelizumab 1 tisagenlecleucel 1 talquetamab 1 selinexor 1 sargramostim 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00172068 2009-12-23

MRD-1

Novartis

Phase 2 Terminated

Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon ⚡